Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.47 |
| ▸ | DAO | P14920 | 2/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.43 |
| ▸ | GFER | P55789 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454496 | 0.87 | HDAC6 (0.47) | EPHX1LMNAHTTTRPV1MAPT | |
| SCHEMBL17288592 | 0.85 | NR4A2 (0.46) | NR4A2SMN1; SMN2LMNAMAPK1HTT | |
| SCHEMBL15932023 | 0.83 | ALDH1A1 (0.46) | SMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL15931901 | 0.81 | EGLN1 (0.52) | NR4A2MEN1KMT2A | |
| SCHEMBL23927275 | 0.77 | TAAR1 (0.58) | EPHX1DAOTRPV1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL17288664 | 0.75 | FDPS (0.46) | EPHX1DAOSMN1; SMN2LMNAHTT | |
| SCHEMBL5445311 | 0.74 | PPARD (0.53) | SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL15931839 | 0.74 | NPC1 (0.64) | MEN1KMT2A | |
| SCHEMBL15932078 | 0.72 | SRD5A2 (0.50) | SMN1; SMN2LMNAMAPK1HTT | |
| SCHEMBL11671597 | 0.71 | NR4A2 (0.44) | EPHX1DAONR4A2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043062-A1 | Isoxazoles as peptide deformylase inhibitors | ARPIDA A/S (DK) | 2007-02-22 | — | — | US | claimed |
| EP-1664000-A1 | ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS | Arpida A/S (DK) | 2006-06-07 | — | — | EP | claimed |
| WO-2005026133-A1 | ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS | ARPIDA A/S (DK) | 2005-03-24 | — | — | WO | claimed |
| US-20070043062-A1 | Isoxazoles as peptide deformylase inhibitors | ARPIDA A/S (DK) | 2007-02-22 | — | — | US | disclosed |
| US-20070043062-A1 | Isoxazoles as peptide deformylase inhibitors | ARPIDA A/S (DK) | 2007-02-22 | — | — | US | disclosed |
| US-20070043062-A1 | Isoxazoles as peptide deformylase inhibitors | ARPIDA A/S (DK) | 2007-02-22 | — | — | US | disclosed |
| EP-1664000-A1 | ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS | Arpida A/S (DK) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026133-A1 | ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS | ARPIDA A/S (DK) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043062-A1 | Isoxazoles as peptide deformylase inhibitors | PDF, MRPL21, PEPD | EPHX1 1420/4885DAO 476/4885NR4A2 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.